Sensitization to Hymenoptera venom marker allergens: Prevalence, predisposing factors, and clinical implications

2018 ◽  
Vol 48 (12) ◽  
pp. 1735-1743 ◽  
Author(s):  
Johanna Stoevesandt ◽  
Christine Hosp ◽  
Andreas Kerstan ◽  
Axel Trautmann
Keyword(s):  
Predisposing Factors ◽  
Clinical Implications ◽  
Hymenoptera Venom ◽  
Marker Allergens

Prevention of the development and maintenance of paediatric chronic pain and disability

2013 ◽  
pp. 39-44 ◽  
Author(s):  
M. Gabrielle Pagé ◽  
Anna Huguet ◽  
Joel Katz
Keyword(s):  
Chronic Pain ◽  
Prognostic Factors ◽  
Protective Factors ◽  
Theoretical Models ◽  
Predisposing Factors ◽  
Clinical Implications ◽  
Essential Step

Understanding the predisposing factors that confer a greater risk of developing chronic pain is an essential step in pain prevention and management. This chapter focuses on current theoretical models that can inform prevention of paediatric pain and disability. We review the literature on known risk/protective factors, markers, correlates, and prognostic factors for the transition to chronic pain and disability across a variety of pain conditions. We distinguish between primary, secondary, and tertiary levels of pain prevention and discuss the clinical implications of this distinction.

Prevention of the development and maintenance of pediatric chronic pain and disability

2021 ◽  
pp. 47-56
Author(s):  
Brittany N. Rosenbloom ◽  
M. Gabrielle Pagé ◽  
Anna Huguet ◽  
Joel Katz
Keyword(s):  
Chronic Pain ◽  
Prognostic Factors ◽  
Protective Factors ◽  
Theoretical Models ◽  
Persistent Pain ◽  
Predisposing Factors ◽  
Clinical Implications ◽  
Pediatric Pain ◽  
Essential Step ◽  
Pediatric Chronic Pain

Understanding the predisposing factors that confer a greater or lesser risk of developing chronic, or persistent, pain is an essential step in chronic pain prevention and management. This chapter focuses on current theoretical models that can inform prevention of pediatric pain and disability. We review the literature on known risk/protective factors, markers, correlates, and prognostic factors for the transition to chronic pain and disability across a variety of pain conditions. We distinguish between primary, secondary, and tertiary levels of pain prevention and discuss the clinical implications of this distinction.

scholarly journals Marker allergens in Hymenoptera venom allergy — Characteristics and potential use in precision medicine

2020 ◽  
Author(s):  
Simon Blank ◽  
Maria Beatrice Bilò ◽  
Johannes Grosch ◽  
Carsten B. Schmidt-Weber ◽  
Markus Ollert ◽  
...  
Keyword(s):  
Clinical History ◽  
Cross Reactivity ◽  
Positive Test ◽  
Test Results ◽  
Hymenoptera Venom ◽  
Venom Allergy ◽  
Therapeutic Decisions ◽  
Threatening Condition ◽  
Primary Sensitization ◽  
Marker Allergens

Abstract Background A comprehensive diagnostic work-up is essential to ensure adequate patient management for the potentially life-threatening condition of Hymenoptera venom allergy (HVA). This includes an unambiguous identification of the allergy-relevant venom as prerequisite for successful venom-specific immunotherapy (VIT). If the clinical history does not allow the identification of the culprit insect, diagnosis is often hampered by positive test results to various venoms. Modern component-resolved diagnostics (CRD) applying marker allergens of Hymenoptera venoms has created new opportunities which facilitate therapeutic decisions and may allow personalized risk stratification for individual patients. Methods Comprehensive literature search and critical analysis of recently published studies on Hymenoptera venom allergens and CRD. Results and discussion Changing the research focus from whole venom extracts to individual allergenic molecules led to the development of CRD in HVA. The currently available CRD is a valuable tool to resolve cross-reactivity and primary sensitization, particularly in honeybee and vespid venom allergy. Hence, CRD has simplified therapeutic decisions in case of multiple positive test results, especially in patients who were not able to identify the culprit insect or in cases of discrepancies between clinical history and classical diagnostic results. Moreover, there is first evidence that sensitization to particular allergens might serve as biomarkers to predict risk for severe side-effects during VIT or even for VIT failure. To date, a clear limitation of CRD is the currently available allergen panel which does not allow a definite resolution of allergy to different vespid species such as yellow jackets and European paper wasps.

Sign in / Sign up

Export Citation Format

Share Document